Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
Holding VIR?
Track your performance easily
VIR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.61 - $23.52
Previous Close$9.37
Volume737.19K
Average Volume (3M)1.18M
Market Cap
$1.27B
Enterprise Value-$126.01M
Total Cash (Recent Filing)$1.51B
Total Debt (Recent Filing)$111.67M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 01, 2024EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.01
Shares Outstanding136,058,680
10 Day Avg. Volume2,027,019
30 Day Avg. Volume1,176,075
Standard Deviation0.32
R-Squared0.00738
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.78
Price to Sales (P/S)129.51
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.01
Enterprise Value/Gross Profit-3.43
Enterprise Value/Ebitda0.37
Forecast
1Y Price Target
$30.75Price Target Upside221.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Vir Biotechnology News
Bulls Say, Bears Say
Bulls Say
Clinical DataInterim Ph2 SOLSTICE data reviewed and final results on track, with a focus on the de novo combination cohort of tobevibart + elebsiran, in which 100% of patients had a virologic response.
Financial PerformanceWith ~$1.5B in cash on hand, management noted they were open to BD activities bringing in early stage immunology assets and expanding beyond virology and into oncology.
Research And DevelopmentVir possesses internal expertise on immunology broadly and has platform technologies including AI informed mAb engineering as well as T Cell viral vectors.
Bears Say
Approval ChallengesApproval based on single-arm without a placebo comparator will be less likely and much more difficult.
Clinical DevelopmentClinical development in CHB progresses slower than expected.
Investor ConcernsShares remain range-bound over the mid-term as there are concerns that the value accretive potential from HBV/HDV phase 2 trial updates or progress from the earlier-stage pipeline can offset the company’s cash burn.
---
Ownership Overview
51.49% Insiders
14.45% Mutual Funds
20.48% Other Institutional Investors
13.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $7.61 and its highest was $23.52 in the past 12 months.
What is Vir Biotechnology’s market cap?
Currently, no data Available
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Aug 01, 2024 which is 142 days ago.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on May 02, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$1.051 by $0.571.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -$0.9.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 136,058,690 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.48 in its last earnings report, beating expectations of -$1.051. Following the earnings report the stock price went up 13.181%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Among the largest hedge funds holding Vir Biotechnology’s share is Royce & Associates LLC. It holds Vir Biotechnology’s shares valued at 1M.
---
Vir Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.75 (221.32% Upside)
$30.75 (221.32% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 24.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $43.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.69%
12-Months-Change
Fundamentals
Return on Equity
-30.67%
Trailing 12-Months
Asset Growth
-32.71%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
---
VIR Company Deck
---
VIR Earnings Call
Q1 2024
0:00 / 0:00
---
VIR Stock 12 Month Forecast
Average Price Target
$30.75
▲(221.32% Upside)
Technical Analysis
Best Analysts Covering VIR
1 Year
1 Year Success Rate
4/25 ratings generated profit
1 Year Average Return
-33.92%
reiterated a buy rating 7 months ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 16.00% of your transactions generating a profit, with an average return of -33.92% per trade.
---